FILANA THERAPEUTICS, INC. - 8-K Filing

FDA lifts clinical hold on Filana Therapeutics' simufilam IND application, enabling Phase 2a trial in TSC-related epilepsy (Items: 7.01 Regulation FD Disclosure, 8.01 of this Current Report on Form 8-K, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $SAVA

Read the full article at SEC EDGAR

More Regulatory news